FAKTOR-OPTIONSSCHEIN - IONIS PHARMACEUTICALS Share Price

Certificat

DE000MG23894

Market Closed - Bid/Ask 09:35:56 15/05/2024 pm IST After market 12:59:35 am
7.19 EUR +12.52% Intraday chart for FAKTOR-OPTIONSSCHEIN - IONIS PHARMACEUTICALS 6.86 -4.59%
Current month-30.24%
1 month-33.92%
Date Price Change
15/24/15 7.19 +12.52%
14/24/14 6.39 -3.91%
13/24/13 6.65 -5.00%
10/24/10 7 -2.10%
09/24/09 7.15 -10.85%

Delayed Quote Börse Stuttgart

Last update May 15, 2024 at 09:35 pm IST

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying IONIS PHARMACEUTICALS, INC.
Issuer Morgan Stanley
WKN MG2389
ISINDE000MG23894
Date issued 10/04/2024
Strike 28.71 $
Maturity Unlimited
Parity 1.4 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 11.52
Lowest since issue 6.27
Spread 0.06
Spread %0.85%

Company Profile

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Sector
-
More about the company

Ratings for Ionis Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Ionis Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
38.27 USD
Average target price
57.95 USD
Spread / Average Target
+51.42%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW